Study: Low-intensity warfarin has post-THA benefits

05/17/2013 | Healio

Treating patients with low-intensity warfarin for six weeks before total hip arthroplasty was associated with low incidence of bleeding and symptomatic venous thromboembolism in the next three months, according to a study in the journal Thrombosis Research. "Low-intensity warfarin should be considered in future studies to identify the regimen that optimally balances risk of bleeding and symptomatic venous thromboembolism in a real world setting," the authors concluded.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
FDA/Device Technology Attorney
Quarles & Brady
Washington, DC
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Executive Medical Director
Aspirus Network Inc
Wausau, WI
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Director, Membership
The Food and Drug Law Institute
Washington, DC